Evidence map›Paper›PMID 42389577›Full record

ReviewiScience2026

Emerging roles of amphiregulin in disease pathogenesis and therapeutic promise.

Nana Li, Junyi He, Meilin Liu, Lingfeng Zha

Abstract readReview
In one paragraph

Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nana LiDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Junyi HeDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Meilin LiuDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Lingfeng ZhaDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amphiregulin (AREG) is an EGF-like ligand that binds EGFR to activate signaling pathways governing cellular proliferation, differentiation, tissue repair, and immune responses. This review integrates AREG's structural characteristics and signaling mechanisms with its biological functions derived from cell-based and animal models. We critically evaluate AREG's mechanistic involvement in cardiovascular, respiratory, intestinal, neoplastic, and infectious diseases, highlighting its dual roles in tissue protection and pathogenesis. The broader significance lies in discussing AREG's translational potential and associated therapeutic challenges for these diseases.

Indexed as

DiseaseMolecular biology

Identifiers

PMID42389577
PMCPMC13320270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.